ABSTRACT
Started in China's Wuhan district late last year, the coronavirus outbreak has thrown several unprecedented challenges. As per the estimates of International Labour Organisation (ILO), due to COVID 19, over 25 million people are likely to lose job. As per the report published by Gallup Foundation, (Harter, 2020) remote workers percentage jumped from 31% to 62% which is likely to impact employee engagement. Employee working remotely can become “next new normal”. Gallup research survey found a strong association between remote mode of working and employee engagement. Employees having option of work from home are more likely to be engaged in comparison to the one who do not have such options available. (Webcast, 2020). An engaged employee is considered to be the best brand ambassador of any organisation. Such an employee is always willing and interested to go “an extra mile” and gives his best at work. For the purpose of the study, data from secondary sources such as e-newspaper, articles, blogs, journal articles and research papers, reports from government organisations, company reports, review articles etc. are gathered and compiled there after a critical analysis of the same is done with respective to objective of the study. During lockdown as per the detailed review undertaken, seven parameters abbreviated as “EFFECTS” were found to be the most important and relevant for employees working from home and making them engaged with the high level of motivation and dedication. These are Employee Voice,Fun Activities,Feelings of Employees,Emotional support, Compassion, Training and Development and Supervision. The study also provides scope for future researchers. © 2021. Transnational Press London. All Rights Reserved.
ABSTRACT
Background: There is an urgent need for treatments to prevent the progression to severe COVID-19 and hospitalization. Methods: This is a double-blind randomized multicenter study in 36 centers in the U.S. and Puerto Rico investigating the potential of a five-day treatment with nitazoxanide 300 mg extended release tablets in 379 outpatients with mild or moderate laboratory-confirmed COVID-19 with an onset of symptoms no more than 72 hours before inclusion. Key objectives were reduction of duration of symptoms (primary), progression to severe illness (key secondary), hospitalization and viral load. Results: Time to sustained response was not reduced by nitazoxanide (median: 13.28 and 12.35 days for nitazoxanide and placebo). Nitazoxanide treatment provided an 85% reduction in the progression to severe COVID-19 (1/184, [0.5%] nitazoxanide vs. 7/195, [3.6%] placebo). In subjects at high-risk according to CDC criteria, 1/112 (0.9%) of nitazoxanide-treated subjects and 7/126 (5.6%) of placebo-treated subjects experienced progression to severe COVID-19. Treatment led to a 79% reduction in the rate of hospitalization (1/184 [0.5%] nitazoxanide vs. 5/195 [2.6%] placebo). The proportions positive for SARS-CoV-2 RNA and viral load at days 4 and 10 were not reduced. Nitazoxanide was safe and well tolerated. Conclusions: Treatment of mild or moderate COVID-19 with a five-day course of oral nitazoxanide was safe and well tolerated and was associated with an 85% reduction in the progression to severe illness.